Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. NAVN
5. CNC
6. KFY
7. ABBV
8. MU
9. DPZ
10. PLTR

Go back to Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1102.08 --0 (-0%)
Previous Close $1102.08    52 Week High $88.16 
Open $1102.08    52 Week Low $67.88 
Day High $1102.08    P/E 255.11 
Day Low $1102.08    EPS $4.32 
Volume 8,126